Earlier studies have identified a subpopulation of putative cancer stem cells (CSCs) with the phenotype CD44+/CD24-/low [4] and more recently, aldehyde dehydrogenase (ALDH) activity was shown to mark normal as well as malignant mammary stem cells [5]. This evidence concerns the gene CD44 and cancer.